Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of NHL.
|
CAR Construction :
Fig.1 Analysis of antibody binding to CD20 + CHO by whole cell ELISA. Antibody reactivity to CD20 + CHO fixed on a PLL plate was tested. Nishida, M., Usuda, S., Okabe, M., Miyakoda, H., Komatsu, M., Hanaoka, H., ... & Niwa, O. (2007). Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). International journal of oncology, 31(1), 29-40. |
|
CAR Construction :
Fig.2 The anti-CD20 binding activity of CD20-binding polypeptide compositions and immunocytokines. Human Daudi lymphoma cells were incubated with varying concentrations of polypeptide compositions and ICs and relative binding to the cells was assessed by flow cytometry. Carr, F. J., Williams, S., & Gillies, S. D. (2012). U.S. Patent No. 8,147,832. Washington, DC: U.S. Patent and Trademark Office. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD20 (2B8) h(CD3ζ) CAR, pCDCAR1 (CAR-YF706). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
